Core Viewpoint - North Chip Life officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2026, with an issue price of 17.52 yuan per share, marking it as the third company to successfully list under the fifth set of standards and the first domestic medical device company in this category [2] Company Positioning - North Chip Life, established in December 2015 and headquartered in Shenzhen, focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [4] - It is the first domestic medical device company to possess a combination of intravascular functional FFR and imaging IVUS products, breaking the reliance on imported products for clinical precision diagnosis of coronary artery diseases in China [4] Product Overview - The company has accumulated over 20 Class III medical device registrations, with core products including China's first approved domestic 60MHz high-definition IVUS system and the first approved domestic gold standard FFR system, enhancing accessibility to cardiovascular precision diagnosis in China [5][6] - As of the signing date of the prospectus, North Chip Life has 17 approved and in-development cardiovascular interventional medical device products, covering five categories: IVUS diagnostic systems, FFR measurement systems, vascular access products, shockwave balloon treatment systems, and electrophysiological solutions [6] Technological Advancements - In 2025, the company plans to launch the first domestic integrated solution for coronary function and the first domestic peripheral IVUS catheter, achieving a key breakthrough in the electrophysiology field with the "single-shot" technique for pulsed electric field ablation [7] - The TRUEVISION® & VivoHeart® intravascular ultrasound diagnostic system is the first domestically developed IVUS product, featuring industry-leading imaging resolution (60MHz) and speed (100 frames per second) [8] Market Implications - In the context of cardiovascular intervention, IVUS and FFR are not merely auxiliary tools but are core infrastructures that directly influence lesion assessment, surgical strategy, and efficacy evaluation [18] - The long-term value of North Chip Life is not solely dependent on whether a single product can replace imports but on its ability to continuously integrate domestic precision diagnostic tools into real clinical workflows, establishing a verifiable and replicable business model [18]

Core Viewpoint - Boston Scientific's recent quarterly earnings report showed strong revenue and profit growth, but the stock price declined due to concerns over the slower-than-expected growth in the electrophysiology segment, which is critical for investor sentiment [1][5][6]. Overall Performance: Revenue and Profit Exceed Expectations - For Q4 2025, net sales reached $5.286 billion, a year-on-year increase of 15.9% (reported basis) and 12.7% organic growth [2][4]. - Net profit was $672 million, reflecting an 18.7% year-on-year growth, with adjusted earnings per share at $0.80, slightly above market expectations [2][3]. Stock Price Decline: Issues in Key Segment - Despite exceeding overall earnings expectations, Boston Scientific's stock price fell by over 10% in pre-market trading and nearly 15% during the day, primarily due to concerns in the electrophysiology (EP) segment [5]. - The EP segment's growth was approximately 35% year-on-year but fell short of market expectations by about 5 percentage points, leading to a revenue shortfall of approximately $33 million compared to consensus estimates [6][18]. Importance of Electrophysiology Segment - The electrophysiology segment, while not the largest, is one of the most scrutinized by capital markets due to its perceived strategic importance [6]. - The competitive landscape for pulsed field ablation (PFA) technology is intensifying, with Boston Scientific facing pressure on its market share as competitors enter the space [7][18]. Overall Business Growth - Excluding the electrophysiology segment, Boston Scientific's overall business remains robust, with significant growth across various segments [8][9]. - Key segment performances for Q4 included: - Cardiovascular: 18.2% growth - Urology: 13.8% growth - MedSurg: 11.7% growth - Neuromodulation: 11.1% growth - Endoscopy: 10.1% growth [12]. Mergers and Products: Strengthening Multi-Track Layout - In Q4 2025, Boston Scientific continued to pursue mergers and product advancements to diversify its portfolio, indicating a proactive approach to reduce reliance on any single product line [11][13]. - The company completed the acquisition of Nalu Medical and secured multiple agreements related to neurovascular technologies, enhancing its competitive positioning [13]. 2026 Guidance: Continued High Growth - Boston Scientific maintains a strong outlook for 2026, projecting double-digit revenue growth despite already exceeding $20 billion in size, which is uncommon among global medical device giants [15]. Conclusion: Market Reassessing Growth Structure - The key takeaway from the earnings report is not a slowdown in growth but rather a market reassessment of growth structures, emphasizing the importance of multi-segment collaboration over reliance on a single standout product [16][18].

Core Insights - Nina Goodheart, the Senior Vice President and President of Medtronic's Structural Heart and Aortic business, announced her retirement after nearly 20 years with the company, marking the end of a significant career [1][3] Group 1: Leadership Background - Nina Goodheart joined Medtronic in 2007, initially focusing on the Cardiac Rhythm and Heart Failure (CRDM) market, and later held various key management positions [3] - Over the past five years, she led the Structural Heart and Aortic business, witnessing its evolution from a single product competition to a platform-based approach with expanded indications and long-term follow-up [3][5] Group 2: Business Progress During Tenure - Under her leadership, the core focus of Medtronic's Structural Heart business was clear, emphasizing the following: 1. Continuous advancement of the transcatheter aortic valve platform 2. Differentiated layout for transcatheter pulmonary valves 3. Promotion of clinical research and conceptual development [6] - The Evolut series of transcatheter aortic valve systems has seen ongoing iterations, maintaining a leading position in the global TAVR competition, while the Harmony transcatheter pulmonary valve system targets a niche market with high technical barriers [7] Group 3: Conclusion and Industry Implications - Goodheart's retirement is viewed as a normal conclusion of an executive career cycle rather than a sign of business pressure or strategic shifts [9] - The news holds value for industry stakeholders interested in how global leaders in the mature structural heart business achieve long-term stable operations [9]

Core Insights - North Chip Life Technology Co., Ltd. (referred to as "North Chip Life") has officially listed on the STAR Market, marking the first medical IPO of the year and achieving a market capitalization exceeding 20 billion yuan after a significant opening day surge [1][5]. Company Overview - The founder, Dr. Song Liang, is an 80s-born PhD who transitioned from physics to life sciences, identifying a critical technology gap in cardiovascular precision diagnosis upon returning to China [2][3]. - North Chip Life is the first domestic high-end medical device company to successfully list on the STAR Market since the resumption of the fifth set of listing standards, signaling a revival in the medical IPO market [1][5]. Product Development - The company has developed the world's first rapid exchange FFR microcatheter based on MEMS sensors, filling a significant technological gap in the market [3]. - North Chip Life has a total of 17 products approved or in development in the cardiovascular intervention medical device sector, including IVUS systems and FFR systems, addressing various cardiovascular diseases [3]. Financial Performance - North Chip Life achieved revenue of 92.45 million yuan in 2022, 184 million yuan in 2023, and 317 million yuan in 2024, with a net profit of 49.44 million yuan in the first half of 2025 [4]. - The company has successfully turned around from losses in previous years, with a significant increase in revenue and a notable overseas income contribution exceeding 15% [4]. Investment and Support - The company has attracted significant venture capital and private equity investment, with notable backers including Sequoia China, Dazhong Capital, and Qiming Venture Partners [6][9]. - North Chip Life's financing history reflects strong investor confidence, with multiple rounds of funding supporting its growth and product development [8][9]. Market Context - The listing of North Chip Life is part of a broader trend of medical companies preparing for IPOs on the STAR Market, indicating a potential opening of the A-share market for medical listings [11][12]. - The current environment suggests a renewed interest in medical innovation, with several companies lining up for IPOs, reflecting a recovery in the investment landscape after a challenging period [13][14].

来源：新浪证券-红岸工作室 2月4日，春立医疗跌1.24%，成交额4912.14万元。两融数据显示，当日春立医疗获融资买入额685.33万 元，融资偿还334.07万元，融资净买入351.26万元。截至2月4日，春立医疗融资融券余额合计5033.11万 元。 融资方面，春立医疗当日融资买入685.33万元。当前融资余额5032.65万元，占流通市值的0.76%，融资 余额超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina ...

摘 要 ： 中 国 海 关 科 学 技 术 研 究 中 心 牵 头 制 定 的 国 家 标 准 《 快 速 核 酸 检 测 仪 性 能 的 测 定 方 法 》 （GB/T47026-2026）正式发布，填补了我国核酸快检设备性能评价国家标准空白，标志着标准化建设 迈出重要一步。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日，中国海关科学技术研究中心（以下简称海科中心）牵头制定的国家标准《快速核酸检测 仪性能的测定方法》（GB/T 47026-2026）正式发布。该标准系依托海科中心仪器设备验 证与综合评价认证平台，联合该验评平台成员单位、科研院所及国内优秀仪器设备生产企业等 多方技术力量共同起草，为我国首项关于核酸快检设备的性能评价国家标准，成功填补了该领 域空白，标志着我国相关领域标准化建设迈出重要一步。 长期以来， 快速核酸检测仪性能评价缺乏统一的国家级标准 ，给仪器研发、生产质控、用户 选型及行业监管带来诸多不便。该标准系统描述了快速核酸检测仪关键性能指标的测定方法， 为相关工作提供了权威、统一的科学依据。标准制定过程充分体 ...

Core Insights - North Chip Life Technology Co., Ltd. has officially listed on the STAR Market, marking the first medical IPO of the year and achieving a market capitalization exceeding 20 billion yuan shortly after its debut [1][2] - The company was founded by Dr. Song Liang, who identified a critical technology gap in cardiovascular precision diagnosis and has since developed innovative medical devices [1][3] - North Chip Life is the first domestic high-end medical device company to successfully list on the STAR Market since the resumption of the fifth set of listing standards [1][5] Company Background - Dr. Song Liang, born in 1982, graduated from Wuhan University and later obtained a Ph.D. in biomedical engineering from the University of Washington [2] - After returning to China, he established a research lab at the Shenzhen Institute of Advanced Technology and began focusing on clinical needs in cardiovascular disease treatment [2][3] - The company was founded in 2015 and has developed the first domestic FFR system based on MEMS sensors, addressing a significant market gap [3] Product Development - North Chip Life has developed a total of 17 products in the cardiovascular interventional medical device field, including FFR systems and IVUS systems, with clinical applications in over 1,000 hospitals globally [3][4] - The company achieved a market-leading position with its 60MHz high-definition IVUS product shortly after its approval in China [3] Financial Performance - The company reported revenues of 92.45 million yuan in 2022, with projections of 184 million yuan and 317 million yuan for 2023 and 2024, respectively [4] - North Chip Life turned a profit before its IPO, with a net profit of 49.44 million yuan in the first half of 2025, indicating growing recognition in the global market [4] Investment and Support - The company has attracted significant investment from notable venture capital and private equity firms, including Sequoia China and Qiming Venture Partners, reflecting strong confidence in its growth potential [6][9] - North Chip Life has successfully completed multiple funding rounds, with key investors supporting its strategic vision and product development [8][9] Market Context - The IPO of North Chip Life signals a reopening of the A-share market for medical companies, with several other firms also preparing for listings [11][13] - The recent trend indicates a growing interest in domestic medical innovations, with many companies seeking to capitalize on favorable market conditions [12][14]

Core Viewpoint - The successful IPO of Beixin Life Science on the STAR Market marks a significant milestone for domestic high-end medical device companies, signaling a resurgence in the medical IPO market [2][7]. Company Overview - Beixin Life Science, founded by Dr. Song Liang, focuses on precision diagnosis and treatment in the cardiovascular field, particularly addressing the critical technology gap in coronary artery disease [3][4]. - The company has developed the first domestic FFR system based on MEMS sensors, filling a long-standing technological void in China [4][5]. - Beixin Life has a total of 17 approved and in-development products in the cardiovascular intervention medical device sector, covering various diseases [5]. Financial Performance - The company reported a revenue of 92.45 million yuan in 2022, with projections of 184 million yuan in 2024 and 317 million yuan in 2025, indicating a strong growth trajectory [6]. - In the first half of 2025, Beixin Life achieved a revenue of 259 million yuan and a net profit of 49.44 million yuan, with over 15% of revenue coming from overseas markets [6]. Investment and Support - Beixin Life has attracted significant investment from notable VC/PE firms, including Sequoia China and Qiming Venture Partners, demonstrating strong market confidence in its business model and product offerings [8][10]. - The company has successfully completed multiple funding rounds, with the latest being a D+ round led by existing investors, showcasing continued investor interest and support [11][12]. Market Context - The IPO of Beixin Life coincides with a broader trend of increasing medical company IPOs in China, indicating a potential opening of the A-share market for medical firms [14][15]. - Several other medical companies are also preparing for IPOs, reflecting a growing confidence in the sector and the potential for domestic innovations to gain international recognition [15][16].

Group 1 - The A-share market opened lower and experienced significant adjustments, while the healthcare sector showed resilience with major stocks like WuXi AppTec rising over 1% and Aier Eye Hospital increasing by over 2% [1] - The largest healthcare ETF (512170) has seen a net subscription of 2.688 billion yuan over the past 13 days, indicating strong investor interest [1] - The pharmaceutical sector showed mixed performance, with innovative drug concepts mostly declining, while traditional Chinese medicine stocks like Darentang rose over 4% [3] Group 2 - The National Medical Products Administration announced support for the biomanufacturing industry during the 14th Five-Year Plan, aiming to shift the pharmaceutical industry towards systematic innovation and quality growth [5] - Analysts are optimistic about the Chinese medicine sector's recovery driven by policy support, cost improvements, and expected adjustments in the essential drug catalog [5] - Zhongtai Securities is bullish on the raw material drug sector, anticipating price improvements after several years of price declines, with most API product prices at historical lows [5] Group 3 - The largest healthcare ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [5] - The only pharmaceutical ETF (562050) has over 60% allocation in innovative drugs while also considering high-dividend Chinese medicine stocks [5] - As of February 3, 2026, the healthcare ETF has a total scale of 27.5 billion yuan, making it the largest in the market [6]

Group 1 - Tianzhihang Medical Technology Co., Ltd. experienced a stock price increase of 5.17%, reaching 25.23 CNY per share, with a trading volume of 305 million CNY and a turnover rate of 2.72%, resulting in a total market capitalization of 11.505 billion CNY [1] - The company, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots. The revenue composition is as follows: orthopedic surgical navigation robots 58.31%, supporting equipment and consumables 23.86%, technical services 16.49%, and others 1.31% [1] Group 2 - Among the top ten circulating shareholders of Tianzhihang, Huaxia Fund's Huaxia CSI Robot ETF (562500) increased its holdings by 1.6284 million shares in the third quarter, holding a total of 8.7238 million shares, which accounts for 1.93% of the circulating shares. The estimated floating profit today is approximately 10.8175 million CNY [2] - The Huaxia CSI Robot ETF (562500) was established on December 17, 2021, with a latest scale of 26.465 billion CNY. Year-to-date returns are 4.34%, ranking 2777 out of 5566 in its category; the one-year return is 30.24%, ranking 2430 out of 4285; and since inception, the return is 6.23% [2] Group 3 - The fund manager of Huaxia CSI Robot ETF (562500) is Hualong. As of the report date, Hualong has served for 3 years and 169 days, with total fund assets of 39.451 billion CNY. The best fund return during the tenure is 209.94%, while the worst return is -15.08% [3]